How to Get Praluent (Alirocumab) in Kentucky

What Is Praluent and Why Would a Kentucky Patient Need It?

Praluent is a fully human monoclonal antibody that inhibits PCSK9, the protein that degrades LDL receptors on liver cells. By blocking PCSK9, alirocumab increases the liver's ability to clear LDL-C from the bloodstream, typically producing LDL-C reductions of 45 to 60 percent on top of maximally tolerated statin therapy. The FDA approved alirocumab in July 2015 for adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering beyond what diet and statin therapy achieve. [1]

Kentucky has a higher-than-average burden of cardiovascular disease. According to CDC data, Kentucky's age-adjusted heart disease death rate is approximately 220 per 100,000 population, well above the national average of roughly 163 per 100,000. [2] That disease burden means a meaningful share of Kentucky adults carry diagnoses that qualify them for PCSK9 inhibitor therapy under current ACC/AHA guidelines.

The 2018 ACC/AHA Guideline on the Management of Blood Cholesterol specifically recommends that clinicians consider adding a PCSK9 inhibitor for very-high-risk ASCVD patients whose LDL-C remains at or above 70 mg/dL on maximally tolerated statin plus ezetimibe. [3] The guideline states: "For patients with very high-risk ASCVD, if LDL-C level remains above 70 mg/dL while on maximally tolerated statin and ezetimibe therapy, adding a PCSK9 inhibitor is reasonable." [3] That sentence describes a large subset of Kentucky cardiology patients who are currently untreated with PCSK9 inhibitors, many because of access barriers rather than clinical ineligibility.

The Clinical Evidence: Why Praluent Is Prescribed

Praluent's approval rests on strong cardiovascular outcome data that went beyond LDL-C reduction alone. ODYSSEY OUTCOMES enrolled 18,924 patients who had experienced an acute coronary syndrome in the prior 1 to 12 months and were already on high-intensity or maximally tolerated statin therapy. [4] At a median follow-up of 2.8 years, alirocumab 75 to 150 mg every two weeks reduced the composite major adverse cardiovascular event (MACE) endpoint by 15 percent compared with placebo (hazard ratio 0.85 to 95% CI 0.78 to 0.93, P<0.001). [4] All-cause mortality was also numerically lower in the alirocumab arm (3.5% vs. 4.1%, HR 0.85, P=0.026). [4]

A separate phase 3 program, ODYSSEY FH I and FH II, demonstrated that alirocumab reduced LDL-C by approximately 49 percent from baseline in patients with heterozygous FH who were already on statins, with 72 percent of alirocumab-treated patients reaching their LDL-C goal versus 2 percent on placebo. [5]

The drug is administered subcutaneously, and patients inject it themselves using a prefilled auto-injector pen. The starting dose is 75 mg every two weeks; if LDL-C response is inadequate after four weeks, the prescriber may uptitrate to 150 mg every two weeks. A 300 mg dose every four weeks is available for patients who prefer monthly injecting. [1]

Who Can Prescribe Praluent in Kentucky?

Any licensed prescriber with authority to write controlled and non-controlled prescriptions in Kentucky may prescribe alirocumab. That includes MDs, DOs, nurse practitioners (APRNs), and physician assistants (PAs) practicing within their scope. Kentucky APRNs with a collaborative practice agreement or independent prescriptive authority may write the prescription without physician co-signature. [6]

Practically, most Praluent prescriptions in Kentucky originate from cardiologists, lipidologists, and endocrinologists because those specialists are most familiar with the prior authorization documentation required by payers. Primary care physicians and internists prescribe it less frequently, though no regulatory barrier prevents them from doing so.

Kentucky telehealth law (KRS Chapter 311.597) permits prescribing via synchronous audio-video encounters when a prescriber-patient relationship has been established. [7] The DEA's telehealth rules do not apply here because alirocumab is not a controlled substance, so a telehealth provider may prescribe it after an appropriate clinical evaluation conducted entirely online, including review of lipid panels, cardiac history, and current medications.

Getting a Praluent Prescription Through Telehealth in Kentucky

The practical path for a Kentucky patient using telehealth follows four steps.

Step 1: Schedule a lipid-focused telehealth visit. Select a provider licensed in Kentucky who is credentialed to manage dyslipidemia. Several national telehealth platforms, including HealthRX, offer lipid management consults for Kentucky residents.

Step 2: Submit labs before the visit. The prescriber will need a fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides), and ideally a lipoprotein(a) measurement, hepatic function panel, and CPK if there is any concern about statin-related myopathy. Labs drawn at a Quest or LabCorp location in Kentucky are acceptable; results should be no older than 90 days.

Step 3: The clinical encounter. The provider will review your cardiac history, current statin and ezetimibe use, reason for inadequate LDL-C control (intolerance vs. insufficient dose), and confirm a qualifying diagnosis. If you carry a confirmed FH diagnosis under the Dutch Lipid Clinic Network criteria or Simon Broome criteria, document that with prior genetic testing or clinical scoring. [8]

Step 4: Prescription transmission and PA submission. The prescriber sends the prescription electronically to your preferred specialty pharmacy and simultaneously initiates the prior authorization (PA) request to your insurer.

Prior Authorization Requirements in Kentucky

Prior authorization is the single largest barrier to Praluent access in Kentucky. Nearly every commercial plan operating in the state, including Anthem BlueCross BlueShield of Kentucky, Humana, Aetna, and UnitedHealthcare, requires PA before dispensing. [9]

Standard documentation a Kentucky PA packet must include:

• Diagnosis of heterozygous or homozygous FH or established ASCVD (ICD-10 codes E78.01 or I25.10 most commonly used)
• Current LDL-C value (typically must be at or above 70 mg/dL for ASCVD patients, or above 100 mg/dL for FH-only patients, depending on plan)
• Documented trial of at least one high-intensity statin at maximally tolerated dose for a minimum of 90 days
• Documented reason for statin intensification failure (intolerance, residual elevation, or contraindication)
• Evidence of ezetimibe trial unless contraindicated
• Prescriber attestation that alirocumab is being used per FDA-approved labeling [1]

The 2022 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes reiterates that PCSK9 inhibitor access requires documenting high-risk features including recent ACS, multiple major ASCVD events, or LDL-C above 100 mg/dL despite dual oral therapy. [10] Having that documentation organized before submitting the PA can cut processing time from weeks to days.

If the initial PA is denied, Kentucky law gives patients the right to a formal appeal and, if denied again, an independent external review through the Kentucky Department of Insurance. [11] A prescriber-drafted appeal letter citing ODYSSEY OUTCOMES outcomes data and the ACC/AHA guideline recommendation class typically has a higher success rate than a form appeal.

What Labs Are Needed Before Starting Praluent in Kentucky?

Before prescribing alirocumab, a Kentucky provider will order or review the following. A fasting lipid panel is the minimum required for both clinical decision-making and PA documentation. Many insurers will not accept a non-fasting sample for PA purposes. [9]

Additional useful labs include:

• Lipoprotein(a) (Lp(a)): Lp(a) above 50 mg/dL (or above 125 nmol/L) is an independent cardiovascular risk enhancer recognized in the 2018 ACC/AHA guideline. [3] PCSK9 inhibitors reduce Lp(a) by roughly 25 to 30 percent, which may add incremental benefit beyond LDL-C lowering. [12]
• Hepatic function panel (AST, ALT): Baseline liver enzymes are standard prior to initiating lipid-lowering intensification. Alirocumab is not contraindicated in mild hepatic impairment but should be used with caution in moderate-to-severe hepatic impairment. [1]
• CPK (creatine phosphokinase): Relevant if the patient reports any statin-related muscle symptoms at the time of consultation.
• HbA1c or fasting glucose: Relevant for characterizing overall cardiometabolic risk and for payers who want a comprehensive risk profile.
• Thyroid-stimulating hormone (TSH): Hypothyroidism is a reversible cause of elevated LDL-C; excluding it before adding a PCSK9 inhibitor is good clinical practice. [3]

Labs can be drawn at any Kentucky LabCorp, Quest Diagnostics, or hospital outpatient laboratory. Most results are available within 24 to 48 hours.

Praluent Pharmacy Access in Kentucky

Praluent is a specialty drug. Most Kentucky retail pharmacies, including CVS and Walgreens chains, do not stock it routinely. Dispensing typically flows through specialty pharmacy channels such as Accredo (Cigna's specialty arm), CVS Specialty, Walgreens Specialty, or Sanofi's own Praluent Connect program. [1]

Can a 503A compounding pharmacy in Kentucky dispense alirocumab? The short answer is no in a clinically meaningful sense. Alirocumab is a complex biologic monoclonal antibody. Kentucky-licensed 503A compounding pharmacies are authorized to prepare compounded drugs for individual patients, but FDA guidance makes clear that PCSK9 inhibitor biologics are not candidates for traditional small-molecule compounding. [13] A 503A pharmacy cannot reproduce a monoclonal antibody. Patients should obtain branded Praluent through the specialty pharmacy channels listed above.

Shipping timelines in Kentucky: Once a PA is approved and the prescription is processed by a specialty pharmacy, standard shipping to a Kentucky address takes two to five business days with cold-chain packaging. Expedited overnight shipping is available through most specialty pharmacies when the prescriber documents clinical urgency.

Cost and Patient Assistance Programs

The list price for Praluent is approximately $5,850 per month without insurance, making financial assistance programs essential for most patients. [1] Sanofi offers the Praluent copay assistance card, which may reduce out-of-pocket costs to as low as $0 per month for commercially insured patients. Eligibility excludes patients covered by Medicare, Medicaid, or other federal programs. [1]

For uninsured or underinsured Kentucky patients, Sanofi's patient-assistance program provides Praluent at no cost to qualifying individuals below specific income thresholds. Applications are submitted through the Praluent Connect program at 1-844-PRALUENT.

Kentucky Medicaid (the state's fee-for-service program and managed Medicaid plans including Anthem, Humana, and Molina) does not cover Praluent as of early 2025. The absence of Medicaid coverage reflects a formulary decision, not a clinical one, and may change as payer negotiations evolve. For Medicaid-enrolled patients, evolocumab (Repatha) has occasional coverage on some Kentucky Medicaid plans, making it worth a formulary check as an alternative PCSK9 inhibitor. [14]

Transferring a Praluent Prescription to Kentucky

If you have an existing Praluent prescription from another state and are moving to or spending extended time in Kentucky, the process is straightforward. Specialty pharmacies operate nationally, so your current specialty pharmacy can continue shipping to a Kentucky address with no new prescription required, provided the prescription has refills remaining and your insurance coverage is active in Kentucky.

If you need a new Kentucky-based prescriber because your out-of-state provider cannot continue care across state lines, a telehealth provider licensed in Kentucky can initiate a new prescription after reviewing your prior records and confirming continued clinical eligibility. A 90-day supply of documentation, including the most recent lipid panel and the prior authorization approval letter, will accelerate the process. [7]

Monitoring While on Praluent in Kentucky

After starting alirocumab, the ACC/AHA guideline recommends a fasting lipid panel at four to twelve weeks after initiation to confirm response and guide dose adjustment. [3] If the 75 mg dose does not reduce LDL-C below the target threshold, uptitration to 150 mg every two weeks is indicated. [1]

Long-term monitoring is less intensive than for statins. The ODYSSEY OUTCOMES trial showed no excess liver toxicity, myopathy, or new-onset diabetes with alirocumab over a median 2.8 years of follow-up. [4] Annual or biannual lipid panels are sufficient for most patients once a stable dose is established.

Injection-site reactions are the most common adverse effect, occurring in roughly 7.2 percent of patients versus 5.1 percent with placebo in the key trials. [1] They are generally mild and do not require treatment discontinuation. Nasopharyngitis and urinary tract infections appeared at slightly higher rates with alirocumab in some trials, though causality is uncertain given low absolute differences. [5]

Patients in Kentucky who are self-injecting should store Praluent in the refrigerator at 36 to 46 degrees Fahrenheit. Vials or pens may be kept at room temperature for up to 30 days if refrigeration is unavailable during travel. [1]

The Fastest Path to a Praluent Prescription in Kentucky

For most Kentucky patients, the fastest sequence is: order a fasting lipid panel today at a local lab, schedule a telehealth lipid consult with a KY-licensed provider within the next week, and have the prescriber submit the PA simultaneously with the prescription to a specialty pharmacy. Commercial PA decisions typically arrive within five to fifteen business days. [9] With Sanofi's Praluent Connect program handling specialty-pharmacy logistics, the first auto-injector pen can arrive at a Kentucky address in as few as seven days from PA approval.

For patients whose commercial insurance denies coverage, the manufacturer copay program eliminates most or all out-of-pocket cost, so a denial is rarely the end of the road. Patients on Kentucky Medicaid should ask their prescriber whether evolocumab or bempedoic acid is covered as an alternative lipid-lowering option while pursuing a Medicaid formulary exception for alirocumab. [14]